# OnCo record alaunos (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/alaunos/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "alaunos" ;
  schema:name "Alaunos Therapeutics (formerly Ziopharm Oncology)"@en ;
  schema:alternateName "Alaunos Therapeutics"@en, "Ziopharm Oncology"@en, "ZIOPHARM Oncology, Inc."@en ;
  schema:description "Alaunos, previously Ziopharm Oncology, developed non-viral TCR-T cell therapies against neoantigens in solid tumours with MD Anderson, after earlier phase 3 programmes with palifosfamide and darinaparsin; it wound down its clinical work in 2023."@en ;
  schema:url <https://onco.cc/companies/alaunos/>, <https://www.alaunos.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://www.alaunos.com>, <https://clinicaltrials.gov/search?lead=Ziopharm%20Oncology>, <https://en.wikipedia.org/wiki/Ziopharm_Oncology> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/sarcoma/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/glioblastoma/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/> ;
  onco:technologies <https://onco.cc/technologies/tcr-t/> ;
  onco:institutions <https://onco.cc/institutions/md-anderson/> .